ArticleIndian journal of urology : IJU : journal of the Urological Society of India
Predictors of survival after cytoreductive nephrectomy in metastatic renal cell carcinoma: A Real-world perspective.
Article in Indian journal of urology : IJU : journal of the Urological Society of India. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Existing retrospective evidence suggests cytoreductive nephrectomy (CN) may benefit patients suffering metastatic renal cell carcinoma, but optimal patient selection criteria are unclear. We evaluated outcomes following CN to identify factors influencing survival to guide patient selection. Methods: We retrospectively reviewed patients who underwent CN from January 2011 to December 2023. Data on demographics, treatment, and survival outcomes were analyzed. Kaplan-Meier estimates calculated progression-free survival (PFS) and overall survival (OS). Cox regression models identified prognostic factors. Results: Of 1346 surgeries performed for RCC during the study period, 63 were performed with cytoreductive intent. Median (IQR) age was 57 (50-65) years, and 79.4% were male. Median PFS was 13.0 (95% confidence interval [CI], 2.5-23.5) months. Diabetes mellitus (DM) (hazard ratio [HR] 2.4, 95% CI 1.1-5.5, Conclusion: The presence of a single site of metastasis is associated with better OS after CN and can serve as a useful criterion to select patients that are most likely to derive benefit from CN. Presentation with SS, RD/SD, and DM predicts poorer outcomes, informing decision-making for CN in metastatic renal cell carcinoma.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.